Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Business Wire•22/10/2026•08:38 ET
0
Key Highlights
- ➤Niagen Bioscience (NAGE) launches prescription-only liquid at-home injection kit
- ➤Ready-to-inject format targets scalable Niagen Plus telehealth expansion
- ➤Two pilot studies evaluated injectable Niagen in 39 generally healthy adults
- ➤90-day at-home injections were well tolerated with no unexpected adverse events
- ➤Exploratory findings associated injections with improved fatigue, sleep, and skin
Expert Statements
Rob Fried, Chief Executive Officer of Niagen Bioscience
“The liquid Niagen At-Home Injection Kit is a meaningful step in building Niagen Plus into a scalable telehealth platform.”
Rob Fried, Chief Executive Officer of Niagen Bioscience
“Additionally, telehealth partners are central to how we intend to scale Niagen Plus.”
Rob Fried, Chief Executive Officer of Niagen Bioscience
“We believe a ready-to-inject format with fewer steps, backed by new pilot clinical data, provides a superior product for telehealth partners, extending reach beyond our own direct-to-patient channel.”
Niagen Bioscience Launches Niagen(™ )Plus Liquid At-Home Injections to Support Telehealth Expansion
Liquid formulation of Niagen(™ )Plus simplifies at-home administration and is the only at-home injection with clinical outcomes associated with reduced fatigue and improved sleep and skin
Get started
Create a free account to read the full story.